Background: To determine whether a dose-dense regimen improves outcome in early breast cancer patients, we compared outcomes with the same fl uorouracil, epirubicin, and cyclophosphamide (FEC) chemotherapeutic regimen administered every 3 weeks (FEC 21 ) or administered every 2 weeks (FEC 14 including support with fi lgrastim, a granulocyte colony-stimulating factor) in a multicenter phase III randomized trial. Methods: A total of 1214 patients with early-stage breast cancer were randomly assigned to receive six cycles of FEC 14 (604 patients) or of FEC 21 (610 patients). Study endpoints were overall survival and event-free survival. Associations were assessed by multivariable analysis with adjustment for age; tumor size; grade; proliferative rate; and menopausal, lymph node, estrogen receptor, and progesterone receptor status. All statistical tests were two-sided. Results: Patients in the FEC 14 arm had fewer dose reductions or treatment delays or discontinuation (26%) than those in the FEC 21 arm (33%) (difference = 7%, 95% confi dence interval [CI] = 2% to 12%; P = .008). FEC 14 therapy, compared with FEC 21 therapy, was associated with more asthenia (36% versus 29%, difference = 7%, 95% CI = 2% to 12%; P = .01), bone pain (33% versus 4%, difference = 29%, 95% CI = 25% to 33%; P <.001), anemia (38% versus 19%, difference = 19%, 95% CI = 14% to 24%; P <.001), and thrombocytopenia (8% versus 2%, difference = 6%, 95% CI = 4% to 9%; P <.001), but with less leukopenia (12% versus 45%, difference = 33%, 95% CI = 28% to 37%; P <. 
The role of increased dose intensity of chemotherapeutic agents, obtained by increasing the single dose per cycle or the total dose of cytotoxic drugs, has been widely studied in trials of adjuvant breast cancer. Randomized clinical trials found no benefi t from increased doses of cyclophosphamide and doxorubicin compared with the standard levels -i.e., cyclophosphamide at 600 mg/m 2 of body surface area ( 1 , 2 ) and doxorubicin at 60 mg/m 2 ( 3 ) . The only benefi cial effect has been demonstrated among high-risk lymph node -positive patients given epirubicin at 100 mg/m 2 instead of epirubicin at 50 mg/m 2 ( 4 ) .
The method of increasing dose density by administering cytotoxic drugs with a shorter interval between treatments has been less extensively evaluated ( 5 ) . The hypothesis that such a strategy is effective was based, in part, on theories developed by Skipper ( 6 ) and by Norton and Simon ( 7 , 8 ) . In their experimental models, a given dose of drug always kills a certain fraction, rather than a certain number, of exponentially growing cancer cells. However, breast cancer cells proliferate by nonexponential gompertzian kinetics ( 8 ) , and the rate of cancer cell proliferation between treatment cycles is more rapid than that used in exponential models ( 8 ) . Consequently, a treatment designed to kill exponentially growing cells may not be able to kill all gompertzian growing cells. Thus, to determine whether an improved outcome would be achieved by reducing the interval between treatment cycles for breast cancer, in 1990 the Gruppo Oncologico Nord Ovest -Mammella InterGruppo (GONO-MIG) group began a series of trials in patients with metastatic breast cancer ( 9 -11 ) and in patients with early breast cancer treated with adjuvant chemotherapy ( 12 ) . We report the results of the trial in patients with early breast cancer who were randomly assigned to treatment arms with the same chemotherapy regimen administered at the same dose (i.e., fl uorouracil, epirubicin, and cyclophosphamide [FEC] ) but with different intervals between the treatment cycles (i.e., 2 weeks [the FEC 14 arm] or 3 weeks [the FEC 21 arm]).
P ATIENTS AND M ETHODS Patient Population
Women with histologically confi rmed breast cancer who had undergone radical mastectomy or breast-conserving surgery in addition to full ipsilateral axillary lymph node dissection were eligible for enrollment in the study, if they had lymph nodepositive disease with no more than 10 involved axillary lymph nodes or if they had no involved lymph nodes but did have a high risk of recurrence. A high risk of recurrence was defi ned as the presence of one or more of the following criteria: age of 35 years or younger; negative estrogen receptor and progesterone receptor status, defi ned as less than 10 fmol of receptor per milligram of protein or less than 10% positive cells by immunohistochemical analysis; tumor size of at least 2 cm; poor histologic grade; and/ or a high proliferative rate, as determined by a [ 3 H]thymidine labeling index or by an S-phase fraction obtained with fl ow cytometry. Patients who were younger than 70 years were to have received no prior chemotherapy and to have no clinical or radiologic evidence of distant metastases, an adequate number of white blood cells (count of ≥ 3000 white cells per microliter) and of platelets (count of ≥ 100 000 platelets per microliter), adequate hepatic and renal function, and surgery performed not more than 5 weeks before randomization. Written informed consent was obtained from all patients before enrollment.
Study Design and Treatment Regimens
This open-label, phase III, randomized clinical trial was conducted at 21 Italian centers in accordance with the International Good Clinical Practice principles and local ethical and regulatory requirements. The study was approved by the internal review board of the coordinating center, the National Cancer Research Institute in Genoa, Italy. Eligible patients were randomly assigned to treatment by telephone or fax at the central operational offi ce of the Trials Center of the National Cancer Research Institute in Genoa. Patients were assigned to a treatment arm according to stratifi ed random lists that were balanced in blocks of various sizes in random sequence.
Patients were randomly assigned to receive either six courses of FEC 21 (5-fl uorouracil at 600 mg/m 2 , epirubicin at 60 mg/m 2 , and cyclophosphamide at 600 mg/m 2 intravenously on day 1, with 21 days between cycles) or six courses of FEC 14 (the same drugs at the same doses as in FEC 21 but with 14 days between cycles and with the support of fi lgrastim). Filgrastim was selfadministered by patients subcutaneously, at a dose of 5 μ g/kg of body weight/day, from day 4 through day 11 of each cycle; treatment was temporarily interrupted if the white blood cell count was more than 20 000 cells per microliter. Overall, 1214 patients were enrolled (604 in the FEC 14 arm and 610 in the FEC 21 arm).
Dose modifi cation, including treatment interruption and/or dose reduction, is described as follows. On day 1 of the cycle, if grade II or higher leukopenia or grade I -II thrombocytopenia was present, treatment was delayed until recovery. In addition, on day 1 of the cycle, if grade III -IV leukopenia associated with grade I -II thrombocytopenia or grade III -IV thrombocytopenia alone was present, chemotherapy was delayed, and individual doses of the three drugs were reduced by 25% in subsequent cycles. Guidelines for dose modifi cation as a result of nonhematologic toxicity, except hair loss and nausea or vomiting, were as follows: if grade II toxicity was present, treatment was delayed until recovery; and if grade III -IV toxicity was present, treatment was delayed, and doses of the three drugs were reduced by 25% in subsequent cycles.
Patients with tumors positive for the estrogen and/or progesterone receptor received tamoxifen at 20 mg/day for 5 years. Overall, 646 patients received tamoxifen (322 in the FEC 14 arm and 324 in the FEC 21 arm). There was no recommendation on the timing of tamoxifen. After completion of chemotherapy, 153 (47%) of the 322 patients in the FEC 14 arm and 149 (46%) of the 324 patients in the FEC 21 arm received tamoxifen. Postoperative regional radiotherapy limited to the remaining breast was given to patients who received breast-conserving surgery. The radiotherapy dose was 50 Gy in 5 weeks to residual breast tissue. A boost dose to the surgical bed (10 -15 Gy in fi ve fractions of 2 -3 Gy over 1 week) was given to patients who were considered to be at moderate to high risk of local recurrence (defi ned as having an extensive intraductal component of >25%, positive surgical margins, and a tumor size of >1 cm).
Initial staging consisted of medical history, physical examinations, and safety evaluations, including complete blood counts and blood chemistry analyses. An electrocardiogram was obtained at baseline and at the end of chemotherapy. Bone scan, chest radiograph, liver ultrasound, and mammography were also required before patients were randomly assigned to a treatment group. The same group of tests and examinations that were performed at baseline was repeated every year during follow-up. All adverse events and laboratory parameters were graded according to the World Health Organization criteria ( 13 ) . Premenopausal status was defi ned by the occurrence of a menstrual period within 6 months before random assignment. To be defi ned as premenopausal, those women younger than 50 years who had undergone hysterectomy were required to have premenopausal levels of luteinizing hormone or follicle-stimulating hormone before randomization. Chemotherapy-induced amenorrhea was defi ned by the absence of menstrual activity for at least 3 months during chemotherapy or within 3 months after the end of chemotherapy.
Endpoints, Statistical Methods, and Dose Intensity Calculation
The primary study endpoint was overall survival, as estimated from the date of randomization to the date of last contact or death from any cause. Secondary endpoints included toxicity and eventfree survival, in which the events were local relapse, distant relapse, second primary cancer, or death from any cause, whichever came fi rst.
The primary hypothesis of the study was that a 50% increase in the dose intensity of FEC would be associated with a 20% relative reduction in the hazard of death. This reduction corresponds to a 5% -6% absolute increase in 5-year survival, which was estimated to be between 65% and 70% in the control group. Thus, we estimated that for a type I error level of .05 and 80% power, we needed to enroll 700 patients per arm over a 4-year period and to conduct the fi nal analysis after another 6 years of follow-up.
All analyses were conducted according to the intentionto-treat principle, in that all patients randomly assigned to a treatment arm were considered as belonging to the arm to which they had been assigned at randomization. Overall survival and event-free survival were obtained from Kaplan -Meier analyses, and the primary comparison between the two study arms was performed with the log-rank test.
To evaluate the role of various prognostic factors and to test for heterogeneity in the effect of the experimental treatment in the subgroups of patients identifi ed by the various prognostic factors, a series of Cox proportional hazards models were fi tted to overall survival and event-free survival data. The graphical representation of log{ − log[ S(t) ]} against log t , where S(t) is the cumulative survival in each stratum at time t and t is the followup time, was used to confi rm the assumption of proportionality. The covariates included in all models were treatment assignment, age (<50 years, 50 -59 years, or ≥ 60 years), menopausal status (premenopausal or postmenopausal), tumor size ( ≤ 2.0 cm or >2.0 cm), lymph node status (negative or positive), grading (G1, G2, G3, or unknown), estrogen receptor status, progesterone receptor status (negative, positive, or unknown), and proliferative activity (low or high). Modifi cations of a treatment effect in subgroups identifi ed by each of these factors were assessed by including the appropriate treatment by covariate interaction term(s) in the model. The likelihood ratio test was used to evaluate the statistical signifi cance of each interaction term or set of interaction terms. This procedure is equivalent to a test of the homogeneity of the hazard ratios associated with the experimental treatment in strata defi ned by each prognostic factor. Stratum-specifi c hazard ratios (HRs), obtained by the coeffi cients estimated by the same models as e (coeffi cient) (with their 95% confi dence intervals [CIs] ), are presented with their corresponding P values. Only four of the eight subgroup analyses that are presented had been anticipated in the study protocol -the analyses by age, lymph node status, hormonal receptor status, and proliferative activity.
Early results, at a median follow-up of 6.7 years, on the role of HER2 expression in predicting the effi cacy of dose-dense chemotherapy, have been previously reported ( 14 ) . In this study, we updated that analysis.
The dose intensity, defi ned as the amount of drug (expressed as milligrams/meters 2 ) administered per unit time (week), was calculated as previously described ( 15 ) . To calculate dose intensity, we defi ned the duration of treatment as the interval between day 1 of the fi rst cycle and day 1 of the last cycle of chemotherapy. Accelerating the administration of chemotherapy from 3 weeks to 2 weeks, for each cycle, was planned to result in a proportional increase in dose intensity of 50%. All statistical tests were two-sided.
R ESULTS

Patient Characteristics
Because of the sharply declining accrual related to competitive trials, patient enrollment was closed 4.5 years after the start of the study, although the planned sample size of 1400 patients had not yet been reached. From November 1, 1992, through June 30, 1997, 1214 patients were randomly assigned to a treatment arm. Forty patients (3.3%) were later found to be ineligible ( Fig. 1 ). All of these 40 patients were included in all the following analyses. The minimum follow-up was 7 years, and the maximum possible follow-up was 12 years (median follow-up among survivors = 10.4 years). At the time of the fi nal analysis (September 30, 2004), 132 (10.8%) of the 992 living patients had been lost to follow-up. The distributions of the main patient and tumor characteristics were similar in the two treatment arms ( Table 1 ) .
Treatment Administration and Dose Intensity
Approximately 93.6% of patients started and completed six cycles of chemotherapy, with no substantial difference between the two treatment arms. Patients in the FEC 14 arm had fewer dose reductions, treatment delays, or discontinuations (157 [26%] of the 604 patients) than those in FEC 21 arm (202 [33%] of the 610 patients) (difference = 7%, 95% CI = 2% to 12%; P = .008). Eighteen patients from both arms never began chemotherapy, and no data were available for nine patients ( tbl2 Table 2 ). Main toxic effects leading to treatment discontinuation were hematologic (10 patients), gastrointestinal (fi ve patients), chemical phlebitis (four patients), and fever (three patients).
Data were available to calculate dose intensity for 1186 patients (590 in the FEC 14 
Safety
Eighteen patients never started chemotherapy, and no information about toxic effects was available for 12 patients. Toxic effect information was available for 1184 patients and was graded according to WHO criteria ( 13 ) ( tbl3 Table 3 ). Grade 1 or worse toxic effects were more common with the FEC 14 regimen than with FEC 21 regimen: asthenia (36% versus 29%, difference = 7%, 95% CI = 2% to 12%; P = .01), bone pain (33% versus 4%, difference = 29%, 95% CI = 25% to 33%; P <.001), anemia (38% versus 19%, difference = 19%, 95% CI = 14% to 24%; P <.001), and thrombocytopenia (8% versus 2%, difference = 6%, 95% CI = 4% to 9%; P <.001). In contrast, less leukopenia was associated with the FEC 14 (12% versus 45%, difference = 33%, 95% CI = 28% to 37%; P <.001). Grade 2 cardiotoxicity occurred in one patient (0.2%) in each arm.
Grade 4 toxic effects were rare. Only two episodes of nonhematologic grade 4 toxicity were reported. One patient (0.2%) in the FEC 14 arm experienced diarrhea, and one patient (0.2%) in the FEC 21 arm experienced vomiting. Among grade 4 hematologic toxic effects, two patients (0.3%) in the FEC 14 arm and 11 patients (1.8%) in FEC 21 arm had leukopenia, and two patients in FEC 21 arm had grade 4 anemia. Only two episodes of febrile neutropenia, one for each arm, were recorded.
The most common grade 3 treatment-related adverse events were nausea and vomiting (12% in the FEC 14 arm and 11% in the FEC 21 arm). Grade 3 bone pain occurred in 6% of patients in FEC 14 arm but in no patient in the FEC 21 arm. Grade 3 stomatitis occurred in 2.5% of patients in the FEC 14 arm and 1.3% of patients in the FEC 21 arm. Severe asthenia was reported in 1.4% of patients in the FEC 14 arm and in 0.2% of patients in the FEC 21 arm. All the other nonhematologic severe toxic effects occurred in less than 1% of patients, with no meaningful difference between the two treatment arms. Severe leukopenia was more common in the FEC 21 arm (6.7%) than in the FEC 14 arm (2.7%), and anemia was more common in the FEC 14 arm (2.7%) than in the FEC 21 arm (0.3%).
Chemotherapy-induced amenorrhea was assessed in 524 premenopausal patients. Eleven of these 524 patients never began chemotherapy, and 10 had no available data about amenorrhea. Thus, overall, 503 patients had available data about amenorrhea. Chemotherapy-induced amenorrhea occurred in 322 (64%) of the 503 patients -162 (64%) of the 253 patients in the FEC 14 arm and 160 (64%) of the 250 patients in the FEC 21 arm.
The incidence of second primary cancers was similar between the two arms -29 (4.8%) of the 604 patients in the FEC 14 arm and 28 (4.6%) of the 610 patients in the FEC 21 arm. Most of these second primary cancers (27 of 57 cancers) were contralateral breast cancers. No case of acute myelogenous leukemia or myelodysplastic syndrome was reported.
Effi cacy
At a median follow-up of 10.4 years, 222 deaths had been recorded (104 in the FEC 14 arm and 118 in the FEC 21 arm). † Women were considered premenopausal as follows: Premenopausal status was defi ned by the occurrence of a menstrual period within 6 months before random assignment. To be defi ned as premenopausal, women younger than 50 years, who had undergone hysterectomy, were required to have premenopausal levels of luteinizing hormone or follicle-stimulating hormone before randomization.
‡ Tumor grade was determined at each participating center ( 16 ) .
Estimated actuarial 10-year survival ( Fig. 2 ) Fig. 2 , A ) was 63% (95% CI = 57% to 69%) in the FEC 14 arm and 57% (95% CI = 50% to 63%) in the FEC 21 arm ( P = .31).
In multivariable analyses ( tbl4 Table 4 ), after adjustment for age, menopausal status, tumor size, lymph node status, grading, estrogen receptor status, progesterone status, and proliferative activity, we found that a non -statistically signifi cant 13% reduction in the hazard of death was associated with the FEC 14 regimen (HR = 0.87, 95% CI = 0.67 to 1.13; P = .293). The effect on event-free survival was similar (HR = 0.88, 95% CI = 0.71 to 1.08; P = .219). Pathologic tumor size, lymph node status, progesterone status, grading, and proliferative activity were independently associated with overall survival and/or event-free survival in multivariable analyses.
Subgroup Analyses
Because of the limited power of most of these analyses and the problem of multiple comparisons, results from subgroup analyses should be considered exploratory. Although the study was underpowered for subset analysis, we found no evidence that the effect of the treatment type was statistically signifi cantly associated with age, menopausal status, lymph node status, tumor size, estrogen and progesterone receptor status, tumor grade, or proliferative rate ( Table 5 ) . However, among patients younger than 50 years, we observed a suggestion of higher effi cacy associated with the FEC 14 regimen than with the FEC 21 regimen ( Fig. 3 ). In addition, among patients negative for both estrogen and progesterone receptors, the FEC 14 regimen was associated with a better outcome than the FEC 21 regimen; however, no difference in outcome between regimens was observed among those patients positive for one or both receptors ( Fig. 4 ) . We also updated our previous analysis ( 14 ) of the interaction between HER2 status and treatment. Among a subset of 731 patients with available data on HER2 status, we identifi ed a differential effect of dose density between HER2-negative patients and HER2-positive patients. Among the 628 HER2-negative patients, 10-year event-free survival was 65% (95% CI = 57% to 73%) in the FEC 14 arm and 60% (95% CI = 53% to 68%) in the FEC 21 arm ( P = .51); overall survival was 85% (95% CI = 80% to 89%) in the FEC 14 arm and 82% (95% CI = 77% to 87%) in the FEC 21 † From a Cox model in which all variables were initially included as covariates. Covariates not statistically signifi cantly ( P >.10) associated with the outcome were excluded from the model by means of a stepdown procedure that was based on likelihood ratio test. All statistical tests were two-sided.
‡ Tumor grade was determined at each participating center ( 16 ) . § Women were considered premenopausal as follows: Premenopausal status was defi ned by the occurrence of a menstrual period within 6 months before random assignment. To be defi ned as premenopausal, women younger than 50 years, who had undergone hysterectomy, were required to have premenopausal levels of luteinizing hormone or follicle-stimulating hormone before randomization.
|| Excluded from the fi nal model. arm ( P = .22). However, among the 103 HER2-positive patients, 10-year event-free survival was 72% (95% CI = 58% to 85%) in the FEC 14 arm and 44% (95% CI = 27% to 61%) in the FEC 21 arm ( P = .03; P interaction = .043); overall survival was 79% (95% CI = 68% to 91%) in the FEC 14 arm and 60% (95% CI = 44% to 76%) on the FEC 21 arm ( P = .1; P interaction = .192).
D ISCUSSION
Results of our study support the long-term safety of dosedense FEC 14 chemotherapy as adjuvant treatment of early breast cancer; however, dose-dense therapy did not statistically significantly improve outcome. To our knowledge, our study is one of only two mature studies in which the dose-dense hypothesis has been tested in the adjuvant therapy of breast cancer. The only difference in the planned chemotherapy regimens between treatment arms was the interval between treatment cycles (3 weeks in the FEC 21 arm and 2 weeks in the FEC 14 arm). Although we allowed dose reduction or dose delay for toxicity, there were actually slightly fewer dose reductions among patients in the FEC 14 arm than among those in the FEC 21 arm and no differences in the total dose delivered between arms. The difference in the time of delivery resulted in a 48% increase in the dose per unit time in the FEC 14 arm compared with that in the FEC 21 arm.
The long median follow-up (10.4 years) in our study allowed us to obtain information about the long-term safety of dose-dense chemotherapy with fi lgrastim support. The use of fi lgrastim has been hypothesized to be associated with an increased risk of secondary acute myelogenous leukemia and/or myelodysplastic syndrome ( 17 ) ; however, no patients in our study developed acute myelogenous leukemia or myelodysplastic syndrome. Thus, no additional risk of leukemia appeared to be associated with the use of an FEC regimen supported by fi lgrastim. Moreover, the acute toxicity associated with the FEC 21 or FEC 14 regimen was mild and easy to manage. The FEC 14 regimen was associated with a higher incidence of any grade of anemia (38% versus 19%), thrombocytopenia (8% versus 2%), and bone pain (33% versus 4%) than was the FEC 21 regimen, but leukopenia was actually more commonly associated with the FEC 21 regimen than with the FEC 14 regimen. We have previously reported ( 18 ) on the quality-of-life comparisons of patients receiving these regimens that were assessed in terms of psychologic distress in a substudy from three centers and 392 patients; results of that study ( 18 ) indicated that, among early breast cancer patients, the FEC 14 Table 5 . Subgroup analysis of overall survival and event-free survival comparing the FEC 14 † From a Cox model, in which all variables were included as covariates. Interaction terms assessing the homogeneity of the effect of experimental treatment across strata of each covariate were introduced in the model one at a time. P values are from likelihood ratio tests. All statistical tests were two-sided.
‡ Test for interaction. § Women were considered premenopausal as follows: Premenopausal status was defi ned by the occurrence of a menstrual period within 6 months before random assignment. To be defi ned as premenopausal, women younger than 50 years, who had undergone hysterectomy, were required to have premenopausal levels of luteinizing hormone or follicle-stimulating hormone before randomization.
|| Tumor grade was determined at each participating center ( 16 ) .
regimen was associated with higher, but transient and timely reversible, psychologic distress than that of the FEC 21 regimen.
Our results are similar to those reported for Cancer and Leukemia Group B (CALGB) 9741 trial ( 5 ) . This study compared sequential doxorubicin, paclitaxel, and cyclophosphamide with concurrent doxorubicin and cyclophosphamide followed by paclitaxel, each regimen administered every 3 weeks or every 2 weeks with fi lgrastim, and reported that the 2-week schedule was well tolerated, with no excess cases of leukemia, fewer cases of neutropenia, but more cases of anemia than with the 3-week schedule.
Our study was substantially underpowered to detect the planned risk reduction. With 222 recorded deaths and 359 recorded events, our study had an 80% power to detect a reduction in the hazard of death of 32% and a reduction in the hazard of an event of 26%, compared with the planned target difference of a 20% reduction in the hazard of death. This reduced statistical power resulted only partially from the fact that accrual was closed after 4.5 years when 1214 patients, instead of the planned 1400 patients, had been randomly assigned to a treatment arm. The primary reason for the low statistical power was that the mortality rate in our study population was much lower than we expected in 1991. When the study was planned, we assumed a 5-year survival of 65% -70% in the control group on the basis of our previous studies on similar patient populations and on estimates of the survival of patients with early breast cancer. However, the 5-year survival that we observed in our control group was 89%, which refl ects the prognosis of breast cancer patients treated in the late 1990s and which corresponds to a death rate of approximately one-third of that expected.
Among the patient population, a 13% reduced risk of death was associated with the FEC 14 regimen, compared with the FEC 21 regimen (HR = 0.87; 95% CI = 0.67 to 1.13). This value corresponded to an absolute improvement of 2% at a median survival of 10 years. This survival benefi t did not reach statistical signifi cance and appears lower than the 31% reduction in the risk of death reported in the CALGB 9741 study at 3 years of follow-up ( 5 ) . However, analysis of more recent data from the CALGB 9741 trial at 5 years of follow-up ( 19 ) found that the strength of the association between overall survival and dosedense therapy was much more modest. In that update, the proportional benefi t associated with dose-dense therapy was 22% among A estrogen receptor -negative patients and only 1% among estrogen receptor -positive patients (who made up 67% of the patients in that study). Thus, risk reduction in the patient population in that trial was in the range of 10% -20%, which is similar to the range that we observed. Although our study did not have enough statistical power to investigate associations in subsets, we found evidence that the dose-dense strategy was selectively associated with improved outcome among estrogen receptor -negative patients (a 20% reduction in risk), compared with that among estrogen receptor -positive patients (a 2% reduction of risk).
Results of other exploratory subset analyses are also of interest. The benefi t associated with the dose-dense FEC 14 regimen appeared to be restricted largely to patients younger than 50 years; these patients had a statistically signifi cant 34% reduced risk of recurrence (HR = 0.66, 95% CI = 0.46 to 0.94) and a non -statistically signifi cant 27% reduced risk of death (HR = 0.73, 95% CI = 0.46 to 1.16 ). This greater effi cacy seems not to be mediated by a greater activity of FEC 14 in suppressing ovarian function, because the rate of chemotherapy-induced amenorrhea was virtually identical in the two arms. It can be hypothesized that dose-dense FEC 14 chemotherapy works well in the subsets of patients generally defi ned as sensitive to chemotherapy; this group includes young patients ( 20 ) with a negative hormone receptor status ( 21 ) or with tumors that have a high rate of proliferation ( 22 ) . Our data suggest that the best candidates for dosedense anthracycline-based chemotherapy may be patients with at least one of the following characteristics: young age, negative hormone receptor status, or high proliferative rate.
Our updated analysis on the association between HER2 overexpression and the effi cacy of dose-dense therapy reinforced previously reported results ( 14 ) that the benefi t of dose-dense chemotherapy appears to be restricted to HER2-positive patients. At a 10.4-year follow-up, a statistically signifi cant absolute improvement of 28% in event-free survival was associated with the FEC 14 regimen, compared with the FEC 21 regimen. An improvement in overall survival associated with the FEC 14 regimen was also observed in this subgroup, although it was not statistically signifi cant. The outcome among HER2-negative patients was similar between the FEC 14 arm and the FEC 21 arm. The hypothesis that dose-dense therapy is effective in HER2-positive tumors appears to be biologically plausible. If HER2 overexpression is associated with more aggressive and rapidly proliferating tumors ( 23 ) and if the proliferation of cancer cells between cycles of chemotherapy is more rapid in these tumors, then administration of an accelerated or dose-dense chemotherapy regimen might have increased effi cacy.
In addition to its reduced statistical power, our trial had other limitations. First, the trial was designed and conducted according to the information that was available in 1991. The trial sample size was not adequate because a 20% risk reduction was the upper limit of a realistic survival benefi t that might be expected with a 50% increase in dose density from the FEC 21 arm to the FEC 14 arm. A second weakness of our trial was that the epirubicin dose used in the FEC regimen (i.e., 60 mg/m 2 ) was less than the current standard epirubicin dose of 100 mg/m 2 . However, when our study was being planned, data on the superiority of higher doses of epirubicin were not available ( 4 ) , and the FEC regimen containing epirubicin at 60 mg/m 2 was commonly used also by other groups ( 24 , 25 ) . In any case, the dose of epirubicin was the same in both arms and thus should not affect the results of this study.
In conclusion, at a median follow-up of 10.4 years, our results support the long-term safety of the FEC 14 dose-dense chemotherapy regimen with fi lgrastim support as an adjuvant treatment for breast cancer. The dose-dense strategy was not statistically signifi cantly associated with improved outcome, but, because of the limited statistical power of our study and the trend for an improved outcome observed, we cannot rule out the possibility of a modestly improved outcome. Exploratory subset analyses indicate that the dose-dense FEC 14 regimen may be associated with an improved clinical outcome, particularly among younger patients, HER2-positive patients, chemosensitive patients (such as those with tumors that are negative for both estrogen and progesterone receptors), and patients whose tumors have high proliferative activity.
